Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1535 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Jing Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China. Hauptthemen laut MEDLINE: Phosphodiesterase 5 Inhibitors, Liver Diseases. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Vigonvita Life Sciences Co., Ltd.
Abstract (Originalsprache)
TPN171 is a phosphodiesterase‐5 inhibitor. It is currently being developed in China to treat pulmonary arterial hypertension and erectile dysfunction (ED). This study aimed to compare the pharmacokinetics and safety of TPN171 across participants with normal hepatic function and hepatic impairment (HI). An open‐label, single‐dose, parallel‐group study enrolled participants with normal hepatic function (group C) and mild‐to‐moderate HI (groups A and B). In each cohort, 8 participants completed the study. Blood samples were collected up to 72 hours after 10 mg oral TPN171 administration. The maximum plasma concentration (C max ), area under the plasma concentration–time curve from time zero to the last quantifiable concentration (AUC 0‐t ), and AUC extrapolated to infinite time (AUC 0‐∞ ) were compared between the groups. C max , AUC 0‐t , and AUC 0‐∞ were higher in groups A and B than in group C (geometric mean ratios 1.17‐1.20, 1.46‐1.53, and 1.45‐1.54, respectively), while the elimination half‐time was prolonged and clearance was reduced in the HI groups. All adverse events were not serious and no participant withdrew from this study. Considering the increase in TPN171 plasma exposure, the highest dose of 5 mg TPN171 is recommended in patients with ED having mild‐to‐moderate HI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Clinical Development Department, Vigonvita Life Sciences Co., Ltd., Suzhou, China.
Förderung
- Vigonvita Life Sciences Co., Ltd
Zitieren
APA
Zhou, J., Zhang, H., Ding, Y., Wang, Z., Wang, Y., Juan, J., Jiang, Z., & Chen, H. (2025). Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1535
Vancouver
Zhou J, Zhang H, Ding Y, Wang Z, Wang Y, Juan J, et al. Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1535
BibTeX
@article{Zhou2025,
author = {Zhou, Jing and Zhang, Hong and Ding, Yanhua and Wang, Zhen and Wang, Yu and Juan, Jiaxiang and Jiang, Zhicheng and Chen, Hong},
title = {Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase 1 Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1535}
}
EUVIMED